November 7, 2017 — Medtronic plc recently presented positive data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation. The data was presented as a First Report Investigation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, Oct. 29-Nov.

http://www.tctconference.comA new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve Repair System (H-MVRS), an image-guided device based on technology developed at the University of Maryland School of Medicine (UMSOM), is deployed through a small opening between the ribs, and repairs the heart while it continues to beat. The research was presented at the Transcatheter Cardiovascular Therapeutics (TCT 2017) symposium, Oct. 29-Nov. 2 in Denver, and simultaneously published in the Journal of the American College of Cardiology (JACC).

Acutus dipole density EP mapping for ablation procedures.

November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technology news for treating atrial fibrillation (AF or Afib) from the past six months. 

New Technologies to Improve Atrial Fibrillation Ablation

November 6, 2017 — In the Hybrid REvascularization Versus Standards (HREVS) study that evaluated three different revascularization strategies, there was no major difference between the use of coronary artery bypass grafts (CABG), drug-eluting stent percutaneous coronary interventions (DES-PCI) or hybrid coronary revascularization (HCR) using a LIMA-LAD graft plus DES-PCI for the remaining vessels. The data from the trial was presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. 

Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017

November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found no significant difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. Both groups were treated with medical therapy. 

November 6, 2017 — TeraRecton announced the launch of version 4.4.13 of its iNtuition advanced visualization platform, over 175 feature and functionality enhancements. According to the company, these improvements accelerate workflow and enhance clinical capabilities for cardiac magnetic resonance (MR), spine labeling, multiphase breast and prostate MR, transcatheter aortic valve replacement (TAVR) and more.

November 6, 2017 — One year follow-up data from the SCOUT I Early Feasibility Study for the Mitralign Trialign System showed positive results. The data was presented by Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at Columbia University Medical Center / New York-Presbyterian Hospital, New York, and the national principal investigator for the SCOUT I Trial, at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference. 

November 6, 2017 —  The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ST-elevation myocardial infarction (STEMI) found six months of DAPT was non-inferior to 12 months among patients treated with second-generation drug-eluting stents (DES).

November 6, 2017 — Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) in combination with medical therapy had better health outcomes. This included significantly fewer major adverse cardiac events (MACE) after three years at comparable costs than patients who received medical therapy alone.

November 6, 2017 — Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now